March 31, 2023
JCR Pharmaceuticals said on March 30 that it has concluded a deal with Alexion, AstraZeneca Rare Disease, for the development of drugs targeting a neurodegenerative disease by employing its proprietary J-Brain Cargo blood-brain barrier (BBB) penetration technology. The research collaboration,...read more